termsTerm
ICER and health technology assessment
Independent bodies that judge whether a new cancer drug's benefit is worth its price; decisive for coverage outside the US and increasingly inside it.
The Institute for Clinical and Economic Review (US, non-governmental) publishes cost-effectiveness reports and 'fair price' benchmarks; NICE (England), CADTH/CDA (Canada), G-BA/IQWiG (Germany), HAS (France), and PBAC (Australia) formally gate reimbursement. Thresholds of $100,000-150,000 per QALY (ICER) or £20,000-30,000 (NICE) versus oncology prices above $200,000 per year drive negotiations and delays.
Regulatory: what this kind of term is about · animated schematic, not to scale
Category
Regulatory